Based on the theory of dampness toxicity of spleen deficiency and microecology, the molecular mechanism of the immune regulation of CRC by the combination of Zhengqi Liujun Cancer Suppression Decoction and Zhengqi Powder was discussed

Phase 1

Recruiting

• Conditions: colorectal cancer

• Registration Number: ITMCTR2000003574
• Lead Sponsor: The Traditional Chinese Medicine Hospital Affiliated to Southwest

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Patient was diagnosed as CRC by pathological examination at the first or second visit;
(2) Patients without postoperative chemoradiotherapy;
(3) According to the 3rd edition of Internal Medicine of Traditional Chinese Medicine edited by Xue Boyu and Wu Wei, combining years of clinical experience of doctors, syndrome differentiation was characterized by spleen deficiency and dampness syndrome;
(4) Eastern Cooperative Oncology Group (ECOG) score <= 2 and estimated survival time > 3 months;
(5) Patients with 18 ? age ?74 years old; No gender restriction;
(6) Voluntarily enrolled, able to cooperate with research and inspection and sign informed consent;
* Note: Criterion 1 must be met.

Exclusion Criteria

(1) Patients with inflammatory bowel disease (IBD), hemorrhoids, etc.
(2) Unable to cooperate, such as the combination of neurological and mental disorders.
(3) Patients after intestinal ostomy.
(4) Microecological regulators used in the past two weeks.
(5) Patients with severe respiratory, circulatory, urinary, neurological, digestive, hematopoietic system and metabolic diseases are allergic to the Traditional Chinese medicine used in the study.
(6) Women during pregnancy.
(7) Other researchers should not participate in the clinical research according to the judgment of the researcher.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intestinal flora 16SRDNA sequencing;Peripheral blood PD-1 and PD-L1;

Secondary Outcome Measures

Name	Time	Method
survival time;Quality of life;Adverse events;